Study of TQH3906 for active psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests an experimental oral medication called TQH3906 for people with active psoriatic arthritis (PsA), a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if TQH3906 is safe and effective in reducing arthritis symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a diagnosis of psoriatic arthritis for at least 3 months and have active joint symptoms (pain, swelling) now.
- You must have tried at least one previous treatment for psoriatic arthritis that did not work well enough or caused side effects.
- If you take certain arthritis medications, you must have been on a stable dose for a specific time before the study starts.
- You cannot have other autoimmune diseases like rheumatoid arthritis or lupus, or active infections like tuberculosis, hepatitis B or C, or HIV.
- You must agree to use effective birth control during the study and for 30 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medication (zasocitinib) taken by mouth to reduce joint pain, swelling, and skin symptoms in adults with psoriatic arthritis. It is for people whose symptoms have not improved enough with standard treatments.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
This trial tests a new medicine (TQH3906) for people with moderate to severe ulcerative colitis or Crohn's disease that hasn't improved with other treatments. The goal is to see if it can help control inflammation in the gut.
This trial tests an oral medication called TQH3906 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve skin symptoms and is for adults who have not had enough success with other treatments.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.